Culprit-Lesion-Only Versus Multivessel Revascularization Using Drug-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: A Korean Acute Myocardial Infarction Registry-Based Analysis

نویسندگان

  • Hyun Su Jo
  • Jong Seon Park
  • Jang Won Sohn
  • Joon Cheol Yoon
  • Chang Woo Sohn
  • Sang Hee Lee
  • Geu Ru Hong
  • Dong Gu Shin
  • Young Jo Kim
  • Myung Ho Jeong
  • Shung Chull Chae
  • Seung Ho Hur
  • Taek Jong Hong
  • In Whan Seong
  • Jei Keon Chae
  • Jay Young Rhew
  • In Ho Chae
  • Myeong Chan Cho
  • Jang Ho Bae
  • Seung Woon Rha
  • Chong Jin Kim
  • Dong Hoon Choi
  • Yang Soo Jang
  • Jung Han Yoon
  • Wook Sung Chung
  • Ki Bae Seung
  • Seung Jung Park
چکیده

BACKGROUND AND OBJECTIVES In patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease, complete revascularization (CR) for non-culprit lesions is not routinely recommended. The aim of this study was to compare the clinical outcomes of multivessel compared with infarct-related artery (IRA)-only revascularization in patients undergoing primary percutaneous coronary intervention (PCI) for STEMI. SUBJECTS AND METHODS From the Korean Acute Myocardial Infarction Registry (KAMIR) database, 1,094 STEMI patients with multivessel disease who underwent primary PCI with drug-eluting stents were enrolled in this study. The patients were divided into two groups: culprit-vessel-only revascularization (COR, n=827) group; multivessel revascularization, including non-IRA (MVR, n=267) group. The primary endpoint of this study included major adverse cardiac events (MACEs), such as death, myocardial infarction, or target or nontarget lesion revascularization at one year. RESULTS There was no difference in clinical characteristics between the two groups. During the one-year follow-up, 102 (15.2%) patients in the COR group and 32 (14.2%) in the MVR group experienced at least one MACE (p=0.330). There were no differences between the two groups in terms of rates of death, myocardial infarction, or revascularization (2.1% vs. 2.0%, 0.7% vs. 0.8%, and 11.7% vs. 10.1%, respectively; p=0.822, 0.910, and 0.301, respectively). The MACE rate was higher in the incompletely revascularized patients than in the completely revascularized patients (15% vs. 9.5%, p=0.039), and the difference was attributable to a higher rate of nontarget vessel revascularization (8.6% vs. 1.8%, p=0.002). CONCLUSION Although multivessel angioplasty during primary PCI for STEMI did not reduce the MACE rate compared with culprit-vessel-only PCI, CR was associated with a lower rate of repeat revascularization after multivessel PCI.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Pooled analysis of two randomized trials comparing titanium-nitride-oxide-coated stent versus drug-eluting stent in STEMI.

INTRODUCTION AND OBJECTIVES We performed a pooled analysis based on patient-level data from the TITAX-AMI and BASE-ACS trials to evaluate the outcome of titanium-nitride-oxide-coated bioactive stents vs drug-eluting stents in patients with ST-segment elevation myocardial infarction at 2-year follow-up. METHODS The TITAX-AMI trial compared bioactive stents with paclitaxel-eluting stents in 425...

متن کامل

Clinical outcome after primary percutaneous coronary intervention with drug-eluting and bare metal stents in patients with ST-segment elevation myocardial infarction.

BACKGROUND The use of drug-eluting stents (DESs) versus bare metal stents (BMSs) in primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction is a matter of debate. Therefore, we examined the risk of target lesion revascularization (TLR), stent thrombosis, myocardial infarction, and death after the implantation of DES or BMS in primary PCI patients in Weste...

متن کامل

Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI).

OBJECTIVES To confirm whether sirolimus-eluting stents (SES) safely reduce the incidence of restenosis in patients with ST-segment elevation acute myocardial infarction compared with bare-metal stents (BMS). BACKGROUND In the setting of primary angioplasty, stent restenosis occurs in up to 27% of patients. The introduction of drug-eluting stents has drastically reduced the incidence of resten...

متن کامل

-Year Follow-Up After Primary Percutaneous oronary Intervention With a Paclitaxel-Eluting tent Versus a Bare-Metal Stent in Acute T-Segment Elevation Myocardial Infarction Follow-Up Study of the PASSION (Paclitaxel-Eluting Versus onventional Stent in Myocardial Infarction With ST-Segment Elevation) Trial

ackground In primary percutaneous coronary intervention for acute ST-segment elevation myocarial infarction (STEMI), the use of drug-eluting stents (DES) is still controversial. Several randomized ontrolled trials of DES, compared with bare-metal stents (BMS), with short-term follow-up showed a eduction in target lesion revascularization (TLR), but no differences in rates of cardiac death or re...

متن کامل

Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction.

BACKGROUND There is no consensus regarding the safety and efficacy of drug-eluting stents, as compared with bare-metal stents, in patients with ST-segment elevation myocardial infarction who are undergoing primary percutaneous coronary intervention (PCI). METHODS We randomly assigned, in a 3:1 ratio, 3006 patients presenting with ST-segment elevation myocardial infarction to receive paclitaxe...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 41  شماره 

صفحات  -

تاریخ انتشار 2011